C57BL/6JCya-Atl1em1/Cya
Common Name
Atl1-KO
Product ID
S-KO-19022
Backgroud
C57BL/6JCya
Strain ID
KOCMP-73991-Atl1-B6J-VB
Status
When using this mouse strain in a publication, please cite “Atl1-KO Mouse (Catalog S-KO-19022) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
Basic Information
Strain Name
Atl1-KO
Strain ID
KOCMP-73991-Atl1-B6J-VB
Gene Name
Product ID
S-KO-19022
Gene Alias
Fsp1, Spg3, Adfsp, Spg3a, 4930435M24Rik
Background
C57BL/6JCya
NCBI ID
Modification
Conventional knockout
Chromosome
Chr 12 (Mouse)
Phenotype
Datasheet
Application
--
Strain Description
Ensembl Transcript ID
ENSMUST00000021466
NCBI Transcript ID
NM_178628
Target Region
Exon 3
Size of Effective Region
~1.4 kb
Overview of Gene Research
Atlastin-1 (ATL1), a regulator of endoplasmic reticulum (ER) morphology, is crucial for tubular ER formation and protein synthesis [3]. It is involved in the mTOR signaling pathway, which is important in regulating cell growth, proliferation, and survival [1].
ATL1 has been studied in relation to several diseases. In pre-eclampsia (PE), ATL1 is upregulated in patients and placental tissues. Upregulation of ATL1 in HTR-8/SVneo cells inhibits the proliferation and invasion of trophoblast cells via the inhibition of the mTOR signaling pathway [1]. In intracranial aneurysms, the circular RNA circ-ATL1 is increased. Silencing circ-ATL1 suppresses vascular smooth muscle cell (VSMC) migration, proliferation, and phenotypic modulation, suggesting its role in aneurysm development [2]. Additionally, ATL1 is one of the causative genes of hereditary spastic paraplegia (HSP). Mutations in ATL1 can lead to a range of symptoms, and genotype-phenotype correlations have been explored, with de novo variants causing complex and severe symptoms in HSP-ATL1 patients [3,4].
In conclusion, ATL1 is essential for ER formation and protein synthesis. Studies on ATL1 in disease models such as pre-eclampsia, intracranial aneurysms, and HSP have provided insights into its role in these conditions. Understanding ATL1 may offer potential targets for treating related diseases.
References：
1. Zhang, Guanli, Feng, Yan, Wang, Min, Liu, Xin. 2022. ATL1 inhibits the proliferation and invasion of trophoblast cells via inhibition of the mTOR signaling pathway. In Journal of biochemical and molecular toxicology, 37, e23237. doi:10.1002/jbt.23237. https://pubmed.ncbi.nlm.nih.gov/36193555/
2. Xu, Jichong, Fang, Chun. 2023. Circ-ATL1 silencing reverses the activation effects of SIRT5 on smooth muscle cellular proliferation, migration and contractility in intracranial aneurysm by adsorbing miR-455. In BMC molecular and cell biology, 24, 3. doi:10.1186/s12860-022-00461-2. https://pubmed.ncbi.nlm.nih.gov/36717793/
3. Shih, Yu-Tzu, Hsueh, Yi-Ping. 2018. The involvement of endoplasmic reticulum formation and protein synthesis efficiency in VCP- and ATL1-related neurological disorders. In Journal of biomedical science, 25, 2. doi:10.1186/s12929-017-0403-3. https://pubmed.ncbi.nlm.nih.gov/29310658/
4. Alecu, Julian E, Saffari, Afshin, Jordan, Catherine, Blackstone, Craig, Ebrahimi-Fakhari, Darius. . De novo variants cause complex symptoms in HSP-ATL1 (SPG3A) and uncover genotype-phenotype correlations. In Human molecular genetics, 32, 93-103. doi:10.1093/hmg/ddac182. https://pubmed.ncbi.nlm.nih.gov/35925862/
Quality Control Standard
Sperm Test
Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.
Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.
Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
